noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
ALAMEDA, Calif., Sept. 07, 2016 -- OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the Annual Gateway Conference on Thursday, September 8, 2016 at 3:30 p.m. ET / 12:30 p.m. PT. The conference will be held at the Four Seasons Hotel in San Francisco.
A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website.
About OncoCyte Corporation
OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.
Investor Contact: EVC Group, Inc. Michael Polyviou / Amanda Prior 646-445-4800 [email protected] / [email protected]
